GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (OTCPK:MBXBF) » Definitions » Debt-to-Asset

Microbix Biosystems (Microbix Biosystems) Debt-to-Asset : 0.18 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Microbix Biosystems Debt-to-Asset?

Microbix Biosystems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.20 Mil. Microbix Biosystems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.78 Mil. Microbix Biosystems's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $27.36 Mil. Microbix Biosystems's debt to asset for the quarter that ended in Dec. 2023 was 0.18.


Microbix Biosystems Debt-to-Asset Historical Data

The historical data trend for Microbix Biosystems's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems Debt-to-Asset Chart

Microbix Biosystems Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.40 0.27 0.18 0.19

Microbix Biosystems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.20 0.19 0.19 0.18

Competitive Comparison of Microbix Biosystems's Debt-to-Asset

For the Biotechnology subindustry, Microbix Biosystems's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbix Biosystems's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's Debt-to-Asset falls into.



Microbix Biosystems Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Microbix Biosystems's Debt-to-Asset for the fiscal year that ended in Sep. 2023 is calculated as

Microbix Biosystems's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microbix Biosystems  (OTCPK:MBXBF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Microbix Biosystems Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbix Biosystems (Microbix Biosystems) Business Description

Traded in Other Exchanges
Address
265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.

Microbix Biosystems (Microbix Biosystems) Headlines

From GuruFocus

Microbix Announces Annual and Special Meeting Voting Results

By GlobeNewswire GlobeNewswire 04-01-2020

Microbix Announces Extension of Warrant Expiry Date

By GlobeNewswire GlobeNewswire 05-18-2023

Microbix Attains Health Canada Establishment Licensing

By GlobeNewswire GlobeNewswire 04-21-2020